CA3132995A1 - Compositions et procedes pour traiter des formes positives de recepteurs des androgenes du cancer - Google Patents

Compositions et procedes pour traiter des formes positives de recepteurs des androgenes du cancer Download PDF

Info

Publication number
CA3132995A1
CA3132995A1 CA3132995A CA3132995A CA3132995A1 CA 3132995 A1 CA3132995 A1 CA 3132995A1 CA 3132995 A CA3132995 A CA 3132995A CA 3132995 A CA3132995 A CA 3132995A CA 3132995 A1 CA3132995 A1 CA 3132995A1
Authority
CA
Canada
Prior art keywords
compound
methyl
cancer
breast cancer
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3132995A
Other languages
English (en)
Inventor
Maureen Caligiuri
Anna Ericsson
Sylvie GUICHARD
Qunli Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forma Therapeutics Inc
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2019/039936 external-priority patent/WO2020006483A1/fr
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of CA3132995A1 publication Critical patent/CA3132995A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Des compositions pharmaceutiques comprenant un composé inhibiteur de CBP peuvent être utilisées pour traiter des patients chez lesquels on a diagnostiqué des formes positives de récepteurs des androgènes du cancer, tels que mCRPC et TNBC, y compris des patients diagnostiqués avec la forme d'épissage AR-v7.
CA3132995A 2019-03-15 2020-03-13 Compositions et procedes pour traiter des formes positives de recepteurs des androgenes du cancer Pending CA3132995A1 (fr)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201962819472P 2019-03-15 2019-03-15
US201962819490P 2019-03-15 2019-03-15
US201962819482P 2019-03-15 2019-03-15
US201962819476P 2019-03-15 2019-03-15
US201962819487P 2019-03-15 2019-03-15
US62/819,472 2019-03-15
US62/819,490 2019-03-15
US62/819,476 2019-03-15
US62/819,482 2019-03-15
US62/819,487 2019-03-15
US201962821660P 2019-03-21 2019-03-21
US62/821,660 2019-03-21
PCT/US2019/039936 WO2020006483A1 (fr) 2018-06-29 2019-06-28 Inhibition de la protéine de liaison à creb (cbp)
USPCT/US2019/039936 2019-06-28
PCT/US2020/022823 WO2020190792A1 (fr) 2019-03-15 2020-03-13 Compositions et procédés pour traiter des formes positives de récepteurs des androgènes du cancer

Publications (1)

Publication Number Publication Date
CA3132995A1 true CA3132995A1 (fr) 2020-09-24

Family

ID=72521203

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3132995A Pending CA3132995A1 (fr) 2019-03-15 2020-03-13 Compositions et procedes pour traiter des formes positives de recepteurs des androgenes du cancer

Country Status (7)

Country Link
EP (1) EP3938365A4 (fr)
CN (1) CN113784967B (fr)
AU (1) AU2020241709B2 (fr)
BR (1) BR112021018266A2 (fr)
CA (1) CA3132995A1 (fr)
MX (1) MX2021011154A (fr)
WO (1) WO2020190792A1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010110380A1 (fr) * 2009-03-27 2010-09-30 興和株式会社 Composé de pipéridine condensé et agent pharmaceutique le contenant
JP5911476B2 (ja) * 2010-05-26 2016-04-27 スノビオン プハルマセウトイカルス インコーポレイテッド ヘテロアリール化合物及びその使用方法
WO2015074064A2 (fr) * 2013-11-18 2015-05-21 Bair Kenneth W Compositions de tétrahydroquinoline utilisées comme inhibiteurs de protéines à bromodomaine et domaine extraterminal (bet)
CN107531690B (zh) * 2014-11-27 2020-11-06 基因泰克公司 用作CBP和/或EP300抑制剂的4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶-3-胺化合物
WO2017197056A1 (fr) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères ciblant un bromodomaine pour la dégradation de protéines cibles
TWI846350B (zh) * 2017-09-15 2024-06-21 美商佛瑪治療公司 作為ＣＢＰ／ｐ３００抑制劑之四氫－咪唑並喹啉化合物
MX2023013508A (es) * 2018-06-29 2023-12-13 Forma Therapeutics Inc Inhibicion de la proteina de union a creb (cbp).

Also Published As

Publication number Publication date
CN113784967B (zh) 2024-07-26
CN113784967A (zh) 2021-12-10
BR112021018266A2 (pt) 2022-02-01
AU2020241709B2 (en) 2025-12-04
EP3938365A4 (fr) 2023-01-25
EP3938365A1 (fr) 2022-01-19
MX2021011154A (es) 2021-10-22
AU2020241709A1 (en) 2021-09-23
WO2020190792A1 (fr) 2020-09-24

Similar Documents

Publication Publication Date Title
JP2020200308A (ja) Ｎａｓｈ／ｎａｆｌｄおよび関連疾患治療のための組合せ
WO2021046382A1 (fr) Composés inhibiteurs de rip1 et leurs procédés de fabrication et d'utilisation
AU2022340664A1 (en) Novel ras inhibitors
US12378242B2 (en) Inhibiting CREB binding protein (CBP)
TWI846350B (zh) 作為ＣＢＰ／ｐ３００抑制劑之四氫－咪唑並喹啉化合物
KR20240041719A (ko) 신규한 티오펜 화합물
US11203597B2 (en) Crystalline spirocyclic compound, a dosage form containing, a method for using in treatment of disease, and a method for recrystallizing
EA025837B1 (ru) Замещенные аннеллированные пиримидины и триазины
US12150941B2 (en) Process for preparing substituted pyrazolo[1,5-a]pyrazines
EP3713923A1 (fr) 2-phénylpyrimidine-4-carboxamides à utiliser en tant qu'inhibiteurs d'ahr
CN115443276A (zh) 吡啶并嘧啶酮衍生物及其作为芳烃受体调节剂的应用
WO2020224652A1 (fr) Inhibiteurs de protéase spécifiques de l'ubiquitine, leur procédé de préparation et leur application
JP2023524361A (ja) Ｔｙｋ２活性を阻害する複素環式化合物
WO2018080216A1 (fr) Dérivé de phénylphtalazine, sa méthode de préparation et composition pharmaceutique le comprenant
US20240016795A1 (en) Bromodomain inhibitors for androgen receptor-driven cancers
AU2011318875A1 (en) Antagonist for mutated androgen receptor
KR102097878B1 (ko) 디아미노 피리딘 유도체
CA3132995A1 (fr) Compositions et procedes pour traiter des formes positives de recepteurs des androgenes du cancer
RU2817802C2 (ru) Композиции и способы лечения андроген-рецептор-положительных форм рака
US6673809B2 (en) Tricyclic compounds as MRP1-inhibitors
EP4703358A1 (fr) Agent de dégradation de protéine gspt1 benzo hétérocyclique à six chaînons et son utilisation
CN114585603B (zh) 前列腺素ep4受体拮抗剂化合物
AU2015386039A1 (en) Bicyclic pyridine compound
EP4488267A1 (fr) Antagoniste du récepteur h3 de l'histamine et son utilisation médicale
HK40121805A (en) Histamine h3 receptor antagonist and medical use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231016

EEER Examination request

Effective date: 20231016

EEER Examination request

Effective date: 20231016

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241104

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250224

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250227

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250307

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250307

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250307

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250707

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250707

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW

Effective date: 20250822